Specify a stock or a cryptocurrency in the search bar to get a summary
Oramed Pharmaceuticals Inc
OJU1Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
Analytics
WallStreet Target Price
3.25 USDP/E ratio
4.549Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OJU1
Dividend Analytics OJU1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OJU1
Stock Valuation OJU1
Financials OJU1
Results | 2019 | Dynamics |